Northern Trust
ACTU

Northern Trust’s Actuate Therapeutics ACTU Stock Holding History

Northern Trust’s Portfolio ACTU Stock Details ACTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$268K Sell
97,851
-3,572
-4% -$14.8K ﹤0.01% 3846
2025
Q4 		$621K Buy
101,423
+15,969
+19% +$110K ﹤0.01% 3581
2025
Q3 		$572K Sell
85,454
-240
-0.3% -$1.74K ﹤0.01% 3605
2025
Q2 		$524K Buy
85,694
+31,842
+59% +$278K ﹤0.01% 3630
2025
Q1 		$365K Buy
+53,852
New +$432K ﹤0.01% 3709

Other funds holding ACTU

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return
PVM
Palogic Value Management Dallas, Texas $237M AUM 5.37% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Northern Trust's ACTU Position: Q1 2026 in Review

Northern Trust reduced its Actuate Therapeutics (ACTU) stake by 3.5% in Q1 2026, selling an estimated $14.8K and leaving 97,851 shares worth $268K. The position accounts for ﹤0.01% of the portfolio, ranked #3846.

Northern Trust first reported a position in ACTU in Q1 2025 and has held it in 5 quarters since. The position peaked at $621K in Q4 2025. 61 funds tracked by Wall St. Rank hold ACTU as of Q1 2026.

  • Northern Trust held 97,851 shares of Actuate Therapeutics worth $268K as of Q1 2026.
  • Northern Trust sold 3,572 Actuate Therapeutics shares in Q1 2026, an estimated $14.8K.
  • Actuate Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #3846 holding.
  • Northern Trust first reported a position in Actuate Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Northern Trust's Actuate Therapeutics position peaked at $621K in Q4 2025.
  • 61 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.